Therapeutics
What physicians prescribe, and what the evidence supports.
Tirzepatide earns its first outcomes label
FDA approved tirzepatide to reduce MACE in adults with type 2 diabetes at cardiovascular risk. The claim rests on SURPASS-CVOT against dulaglutide, an active comparator, with an 8% relative reduction.
The Lp(a) drug moved the number, not the outcome
Novartis and Ionis reported topline Phase III results from Lp(a)HORIZON on September 4: 8,323 patients with elevated Lp(a) and established cardiovascular disease on guideline-directed therapy.
Semaglutide, started late, extended life in mice
Female mice started daily semaglutide at 20 months, roughly a human mid-60s, and stayed on it for life. Median lifespan rose from 742 to 834 days, about 12%.
Inside the longevitydocs Peptide Mastermind
If you walked into that room, you could feel it, the curiosity, the energy, the collective intelligence. From biology to regulation, the debate was intense, deeply respectful, and often humbling.
Peptides: meet the doctors speaking at the Mastermind
That’s why we’re bringing together the physicians who study, research, prescribe, and teach about peptides, so you can learn directly from the best how peptides can transform your practice, improve patient outcomes, and keep you at the forefront of modern medicine.
The Sunday edition.
The week in longevity medicine, every Sunday.
Free, delivered by Substack. Unsubscribe any time.